Swedish biopharmaceutical company Mendus AB (STO:IMMU) on Wednesday reported positive topline data from the Phase 1 ALISON trial of vididencel in ovarian cancer patients.

Vididencel stimulated immune responses in 12 out of 17 patients, a potential basis for an anti-tumour response.

The trial also confirmed the drug's strong safety profile with only mild side effects.

Long-term follow-up is ongoing, with the next update expected in Q4 2025.